What was recalled
The U.S. Food and Drug Administration (FDA) has issued a Class II recall affecting a specific batch of prescription cancer medication manufactured by Shilpa Medicare Limited. The product in question is PEMRYDI RTU, which stands for pemetrexed injection, delivered in a single-dose vial format. Specifically, this recall targets the 500 mg/50 mL concentration, which equates to a strength of 10 mg per milliliter. It is critical to understand that this is not a general warning about all PEMRYDI products, but rather a targeted action against specific lots identified by distinct National Drug Codes (NDC) and expiration dates.
The medication was manufactured by Zydus Lifesciences Limited, located in Ahmedabad, India, and subsequently distributed across the United States by Amneal Pharmaceuticals LC, based in Bridgewater, New York. The distribution pattern for this recall is nationwide, meaning that healthcare providers, pharmacies, and hospitals across all 50 states may potentially possess these affected vials. The recall was officially initiated on July 29, 2026, prompting immediate action from regulatory bodies to ensure patient safety.
To help you identify if you or your healthcare provider might be holding a recalled item, it is essential to look at two specific pieces of information: the NDC number and the lot number. The affected products carry the NDC 70121-2461-1. There are two specific lots included in this recall notice. The first lot is P400157, which has an expiration date of August 31, 2026. The second lot is PA00047A, with a later expiration date of September 30, 2027. If you have documentation for these products, such as pharmacy receipts or hospital inventory logs, these numbers are the primary keys to determining whether your vials are part of this specific recall event.
This is a Class II recall, which indicates that use of the product could cause temporary health problems or pose a slight threat of a serious nature. The classification underscores the seriousness of the issue without suggesting it is an immediate, life-threatening emergency in every instance, but it does require prompt attention. The scope is limited to these specific vials distributed by Amneal Pharmaceuticals. No other brands or formulations of pemetrexed are mentioned in this specific FDA notice. If your medication does not match the NDC 70121-2461-1 exactly, or if the lot numbers do not match P400157 or PA00047A, it is not part of this recall. However, because cancer treatments are complex and highly monitored, any uncertainty should be addressed directly with your healthcare provider or pharmacist to ensure absolute clarity.
The hazard, explained
When you encounter a medical product that has changed color, it is natural to feel uneasy, but understanding exactly what that change signals can help you make a calm, informed decision. In this specific recall of PEMRYDI RTU (pemetrexed injection), the core issue is not merely cosmetic; it is a visible indicator that the chemical integrity of the drug may have been compromised. The U.S. Food and Drug Administration (FDA) identified this hazard after receiving market complaints describing a distinct green to dark green discoloration in certain single-dose vials. While pemetrexed solutions are typically expected to be clear, colorless to slightly yellow, the emergence of deep green hues suggests that the solution has undergone an unintended chemical reaction.
To understand why this matters, it helps to look at what pemetrexed actually does. Pemetrexed is a chemotherapy agent classified as an antifolate antimetabolite. Its primary mechanism of action involves interfering with enzymes required for the synthesis of purines and pyrimidines, which are essential building blocks for DNA and RNA. When these processes are disrupted in rapidly dividing cells, it can stop cancer growth. However, this delicate chemical balance is fragile. The appearance of a green discoloration often points to degradation products forming within the vial. These degradation products may result from various factors, including exposure to light, temperature fluctuations during storage or transport, or inherent instability in the formulation over time. When a drug degrades, it breaks down into different chemical compounds that were not part of the original, tested formula.
The danger here is twofold: efficacy and safety. First, if the active ingredient has degraded, the concentration of pemetrexed in the vial may be lower than labeled. This means a patient could receive a sub-therapeutic dose, potentially allowing cancer cells to continue growing unchecked or becoming resistant to treatment. Second, and more critically, the degradation byproducts themselves may be harmful. Unstable pharmaceutical solutions can produce impurities that are toxic or cause severe adverse reactions when introduced directly into the bloodstream. Since this is an intravenous injection, any particulate matter or altered chemical structure bypasses the body’s natural filtration systems found in the digestive tract and goes straight into circulation, posing a significant risk of infusion reactions, organ stress, or other complications.
It is important to distinguish between general stability issues and acute contamination. In this case, the hazard is tied to specific lots (P400157 and PA00047A) distributed by Amneal Pharmaceuticals LC. The green tint is a clear "stop" signal. It indicates that the manufacturing quality control or the storage conditions failed to preserve the drug’s stability. For a life-saving medication like pemetrexed, consistency is everything. A discolored solution breaks the chain of trust between the manufacturer and the patient, rendering the product unsafe for clinical use. Therefore, the FDA has classified this as a Class II recall, which denotes a situation where use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote—but only because the risk is being managed through strict avoidance of the product.
Who is most at risk
To understand who is most at risk with this specific recall, it is essential to first recognize the nature of the product involved. PEMRYDI RTU (pemetrexed injection) is a prescription-only medication classified as a serious pharmaceutical agent. Unlike over-the-counter remedies that might cause minor discomfort if taken incorrectly, pemetrexed is a potent chemotherapy drug used primarily in the treatment of certain cancers, such as non-small cell lung cancer and malignant pleural mesothelioma. Because it targets rapidly dividing cells, its use requires careful medical supervision, and the individuals receiving this treatment are already navigating a vulnerable phase of their health journey.
The primary group at risk here consists of patients who have been prescribed or are currently undergoing treatment with the specific lots identified in this FDA recall. These are not casual users; they are individuals relying on this medication as part of a critical, life-altering medical regimen. The hazard involved is discolored solution—specifically, vials that have turned green to dark green. While discoloration in injection solutions can sometimes be a sign of chemical degradation or contamination, the exact clinical impact of this specific defect has not been fully detailed by the manufacturer. Therefore, the risk is twofold: the potential for the drug to be less effective than intended, and the possibility that degraded components could cause an adverse reaction when injected into the body.
Elderly patients, who often comprise a significant portion of oncology populations, may be particularly vulnerable. As we age, our bodies process medications differently, and our immune systems may be less robust. For these individuals, any interruption in their treatment plan or any exposure to an improperly prepared medication can lead to more severe complications than it might for a younger, healthier patient. Furthermore, because pemetrexed is administered intravenously (RTU stands for Ready-To-Use), the risk of direct introduction of any particulate matter or degraded chemical byproducts into the bloodstream is immediate and systemic.
It is also important to note that this recall affects a nationwide distribution pattern. This means that patients across the United States, regardless of their geographic location, could potentially have received an affected vial. The risk is not limited to a specific region but is spread among all healthcare facilities and pharmacies in the country that stock or dispense these specific lots from Amneal Pharmaceuticals LC. Consequently, any patient who has recently received this injection at a hospital, clinic, or infusion center should be considered potentially at risk until they have verified their lot number.
While the general public is not at risk because this is a prescription drug, those in close contact with patients undergoing treatment, such as family caregivers, also share an indirect stake in ensuring these medications are safe. They are often the ones who might notice discrepancies in the appearance of the medication before it is administered. For now, the most critical group remains the patients themselves, whose health outcomes depend on the integrity of every dose they receive.
How to tell if you have the recalled item
Verifying whether your medication is part of this FDA recall requires a careful, methodical check of the packaging and documentation. Because this involves a prescription injectable drug used for serious medical conditions, accuracy is critical. Do not rely on memory or general descriptions; you must inspect the physical vial and its accompanying box against the specific details provided in the official recall notice. The goal here is to match four distinct pieces of information: the brand name, the National Drug Code (NDC), the lot number, and the expiration date. If even one of these does not match the details below, your product is likely safe from this specific issue.
First, locate the cardboard box that originally held the medication. On the side or back panel, you will find a label with printed text. Look specifically for the brand name PEMRYDI RTU (pemetrexed injection). It is crucial to note that this recall applies only to this specific branded product manufactured by Zydus Lifesciences Limited and distributed by Amneal Pharmaceuticals LC. If your vial is labeled under a different brand or manufacturer, it is not part of this recall.
Next, examine the National Drug Code (NDC). This unique identifier helps distinguish between different strengths and packaging configurations of the same drug. For this recall, you are looking for the NDC 70121-2461-1. This code corresponds to the 500 mg/50 mL (10 mg/mL) single-dose vial. If your box lists a different NDC, even if it is also PEMRYDI RTU, it may be a different batch or configuration and is not included in this specific alert.
The most critical step is checking the lot number and expiration date. Manufacturers assign unique lot numbers to track production batches. The recall affects only two specific lots of PEMRYDI RTU. Check your box for either of the following lot numbers:
- P400157, with an expiration date of 08/31/2026
- PA00047A, with an expiration date of 09/30/2027
Printed on the vial itself, you should also find these same lot and expiration details. However, packaging labels are often clearer and easier to read. If your product has a different lot number or an expiration date outside of the two ranges listed above, it is not part of this recall.
If you have already opened the box or lost the packaging, check your prescription label from the pharmacy or any medical records you may have kept. These documents often list the NDC and lot number. If you cannot verify these details with certainty, contact your pharmacist or healthcare provider immediately. They can help you look up the information based on your prescription history.
Remember, this recall is due to a potential discoloration of the solution, ranging from green to dark green. While you should inspect the liquid in the vial for any unusual color changes, do not discard or use the medication based solely on appearance. The official identification must always rely on the NDC, lot number, and expiration date printed on the packaging. If your product matches the details above, stop using it immediately and follow the steps outlined in the remedy section of this recall notice.
What to do — step by step
If you are a healthcare professional or a patient who has received this specific batch of PEMRYDI RTU (pemetrexed injection), the most critical first step is to immediately cease using any vials that match the recalled lot numbers. Because the recall involves a Class II hazard—meaning it could cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse effects is remote—you must treat this with urgency but without panic. The primary action is to quarantine the product. Do not attempt to use the medication for any purpose, even if the solution appears clear in certain lighting conditions. The FDA has reported that the discoloration can range from green to dark green, and since visual inspection alone may not always reliably distinguish affected vials from safe ones, strict adherence to lot number verification is essential.
Your next step is to contact your supplier or distributor immediately. In this specific case, the product was distributed by Amneal Pharmaceuticals LC in Bridgewater, New York. You should reach out to their customer service or recall coordination team to report that you possess inventory associated with NDC 70121-2461-1, specifically lots P400157 (expiration date 08/31/2026) and PA00047A (expiration date 09/30/2027). It is important to provide them with the exact quantity of vials you have on hand so they can track the scope of the recall. While the official remedy details for this specific recall are not currently stated in the public FDA database, manufacturers and distributors typically arrange for the return or destruction of the product at their expense. Do not attempt to dispose of these vials in regular household trash or standard medical waste bins until you have received explicit disposal instructions from Amneal Pharmaceuticals or your healthcare facility’s pharmacy department.
If you are a patient who has already been administered this drug, do not stop your prescribed treatment regimen abruptly without speaking to your oncologist or prescribing physician. The discoloration issue relates to the stability and appearance of the unopened vial; however, your care team needs to know exactly which lot was used in your treatment so they can monitor you for any potential issues. Your doctor will determine if additional monitoring is necessary and will help arrange for a replacement dose using a non-recalled lot from a different manufacturer or batch, ensuring your cancer treatment continues without dangerous gaps. Keep all packaging materials, including the vial box and any remaining documentation, as these may be required for the return process.
Finally, monitor your local pharmacy or hospital inventory system to ensure that no further units of this NDC are being dispensed. Healthcare facilities should conduct a quick audit of their sterile drug rooms to identify any misplaced vials from these lots. By taking these concrete steps—quarantining the product, contacting the distributor Amneal Pharmaceuticals, consulting your doctor for patient-specific care, and verifying inventory—you ensure that the recall is handled safely and efficiently, protecting both individual health and public safety standards.
Your refund, repair, or replacement options
One of the most important details in any recall notice is understanding exactly what the manufacturer intends to do to fix the problem and how you can get that remedy. In this specific case involving Shilpa Medicare Limited’s PEMRYDI RTU (pemetrexed injection), the official FDA recall facts present a somewhat unusual situation for consumers who might be expecting a straightforward return-for-refund process. The record explicitly states that the remedy is "not stated." This does not mean there is no plan to fix the issue; rather, it means that the specific terms of the resolution—such as whether you will receive a full refund, a credit, or a replacement product—have not been publicly detailed in this initial recall classification document.
It is crucial to understand why this information might be missing from the immediate public record. PEMRYDI RTU is a prescription-only medication (Rx only) used in cancer treatment, distributed by Amneal Pharmaceuticals LC and manufactured by Zydus Lifesciences Limited. Because this is a Class II recall, indicating a temporary or medically non-life-threatening situation, the focus is often on stopping distribution to healthcare facilities rather than managing individual consumer returns. In many pharmaceutical recalls of this nature, the "remedy" is managed through the supply chain. Healthcare providers and pharmacies are typically instructed by the distributor to return the affected lots directly to the supplier for destruction or inspection, rather than issuing refunds to patients. Patients rarely receive direct financial compensation because they have already paid for a service (administration of the drug) or will simply receive a replacement dose from their provider without a separate transactional refund process.
So, what should you do if you believe you have one of these specific vials? Since the remedy details are not listed, you must take proactive steps to get clarity. First, contact your healthcare provider or the pharmacy where you picked up the prescription immediately. They are the primary point of contact for this recall because they deal directly with Amneal Pharmaceuticals LC and Shilpa Medicare Limited. Your pharmacist can check their internal records to see if they have received specific instructions from the distributor regarding these lots (P400157 expiring 08/31/2026 or PA00047A expiring 09/30/2027).
If you are a healthcare facility, such as a hospital or clinic, you should contact Amneal Pharmaceuticals LC directly, as they are the listed distributor. They will have the most current and specific instructions on how to handle the returned inventory, including any shipping labels or credit memos that might be involved. Do not attempt to dispose of these vials in household trash, and do not use them if you suspect discoloration. While we cannot invent contact numbers or email addresses here, Amneal Pharmaceuticals LC and Shilpa Medicare Limited maintain official customer service channels that are updated during active recalls. Your pharmacy or doctor’s office staff will be able to provide you with the correct phone number or portal link to report your specific situation. Remember, in pharmaceutical recalls, "repair" is not an option; the solution is either a safe replacement of the product or a proper medical alternative determined by your care team.
What can happen if you ignore it
When you are managing a serious medical condition, the last thing you want is to introduce new variables into your treatment plan. However, ignoring a recall notice for a medication like PEMRYDI RTU (pemetrexed injection) carries specific and potentially severe risks that go far beyond mere inconvenience. The core issue here is not just that the drug looks different, but that the visual change—a green to dark green discoloration—serves as a critical warning sign of chemical instability. By continuing to use or administer this product, you are bypassing one of the most important safety checks available: the physical integrity of the solution.
Pemetrexed is a chemotherapy agent used to treat certain types of cancer, including non-small cell lung cancer and malignant pleural mesothelioma. These are powerful drugs that require precise dosing and strict chemical stability to work safely. When a clear solution turns green, it indicates that the active ingredient may have degraded or reacted with other components in the vial. This degradation can happen for several reasons, such as exposure to improper temperatures, light sensitivity, or manufacturing defects in the vial’s sealing process. If you ignore this sign, you risk receiving a dose that is no longer pure pemetrexed.
The consequences of using a degraded injectable drug are twofold: therapeutic failure and toxic exposure. First, the medication may simply not work. If the active pharmaceutical ingredient has broken down, your body is not receiving the full prescribed dose. In the context of cancer treatment, this means the disease may progress unchecked, allowing tumors to grow or spread while you believe you are being treated effectively. This delay in effective care can have profound impacts on long-term health outcomes.
Second, and perhaps more immediately dangerous, is the risk of adverse reactions from degradation byproducts. When a drug breaks down, it forms new chemical compounds that were never tested for safety. Injecting these unknown substances directly into your bloodstream bypasses your body’s natural filtration systems, such as the liver and kidneys. This can lead to severe allergic reactions, unexpected toxicity, organ damage, or other serious systemic side effects that are not associated with standard pemetrexed use. Because the drug is administered intravenously, these harmful byproducts enter your circulation instantly, leaving no time for your body to mitigate the damage.
Furthermore, there is the risk of particulate matter. While the recall specifically cites discoloration, solutions that change color often also develop microscopic particles or precipitates. Injecting even tiny, invisible solids into a vein can cause blockages in small blood vessels, leading to embolisms or localized tissue damage at the injection site. For patients whose immune systems are already compromised by chemotherapy, introducing any additional foreign material is a significant health hazard.
Finally, ignoring the recall disrupts the medical chain of care. Your healthcare provider prescribed this specific medication based on its known safety profile. Using a recalled unit means you are effectively self-administering an unverified treatment. This makes it difficult for doctors to interpret your body’s response—if you experience side effects, they won’t know if they are from the cancer, the standard drug, or the degraded product. This confusion can lead to misdiagnosis of your condition’s status and complicate future treatment decisions. The safest path is always to return the product immediately so that your care team can provide a verified, safe alternative without delay.
Staying safe: broader tips
When it comes to prescription medications, particularly injectables like pemetrexed, your role as a consumer extends far beyond simply taking the pill or receiving the injection at a clinic. While the FDA and manufacturers work tirelessly behind the scenes to ensure quality control, there are practical, everyday steps you can take to safeguard your health when handling pharmaceutical products. One of the most critical yet often overlooked aspects of medication safety is visual inspection. Never assume that a vial looks correct just because it came from a reputable pharmacy or hospital. Before any administration, whether by a healthcare professional or in a home-care setting where permitted, always check for clarity and color. Clear solutions should remain clear; any unexpected tinting, cloudiness, or particulate matter is a red flag that warrants immediate questioning. This simple act of looking closely can prevent exposure to compromised drugs before they ever enter your system.
Another vital layer of protection is staying informed about the broader landscape of drug safety. Recalls happen for many reasons, from minor labeling errors to serious contamination issues, and being proactive can help you stay ahead of potential risks. Sign up for email alerts from the FDA’s MedWatch program or your local health department. These notifications don’t just cover high-profile recalls; they also provide updates on safety communications that might affect how you take your regular medications. Additionally, keep a personal medication log that includes lot numbers and expiration dates if possible. While this might seem like extra paperwork, it creates a clear record that can be invaluable if a recall notice is issued for a specific batch. It transforms a potentially confusing situation into a straightforward verification process.
Finally, foster open communication with your healthcare providers. Ask questions about where your medications are sourced and how they are stored. Proper storage conditions—such as temperature control—are essential for maintaining drug integrity until the moment of use. If you ever notice discrepancies in packaging or have concerns about a product’s appearance, do not hesitate to report it. Your vigilance contributes to a larger network of safety that protects not just you, but everyone who might receive that same batch. By combining visual checks, staying informed through official channels, and maintaining open dialogue with your care team, you build a robust defense against the rare but real risks associated with pharmaceutical products.